Citi raised the firm’s price target on Abbott (ABT) to $160 from $135 and keeps a Buy rating on the shares. The analyst also added a “90-day negative catalyst watch” on the shares. The stock “will need to test the litigation waters before further ascent,” the analyst tells investors in a research note. Citi, however, raised estimates for Abbott to reflect the company’s Q4 strength and momentum.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
